Increased urinary CCL2: Cr ratio at 6 months is associated with late renal allograft loss

Transplantation

Volumn 95, Issue 4, 2013, Pages 595-602

  Ho, Julie ^a,b   Wiebe, Chris ^a   Rush, David N ^a   Rigatto, Claudio ^a   Storsley, Leroy ^a   Karpinski, Martin ^a   Gao, Ang ^b   Gibson, Ian W ^a   Nickerson, Peter W ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chemokines; Chronic allograft injury; Monocyte chemoattractant protein 1 (CCL2); Urinary biomarker

Indexed keywords

ANTIBODY; BASILIXIMAB; CREATININE; CYCLOSPORIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CREATININE URINE LEVEL; DELAYED GRAFT FUNCTION; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INDEPENDENT VARIABLE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; PROTEINURIA; REFERENCE VALUE; RENAL GRAFT DYSFUNCTION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CREATININE; DELAYED GRAFT FUNCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MANITOBA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84874666851     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826690fd     Document Type: Article

References (39)

1. Stegall MD, Park WD, Dean PG, et al. Improving long-term renal allograft survival via a road less traveled by. Am J Transplant 2011; 11: 1382.
2. Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Ann Rev Med 2007; 58: 369.
3. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698.
4. Lamb KE, Lodhi S, Meier-Kriesche H-U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450.
5. OPTN/SRTR 2010 Annual Data Report. Dept. of Health & Human Services, Health Resources & Services Administration, Healthcare Systems Bureau, Division of Transplantation. Am J Transplant 2012; 12(suppl 1): 22.
6. Knoll G, Muirhead N, Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5: 1719.
7. Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970.
8. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. New Engl J Med 2003; 349: 2326.
9. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
10. Chapman JR. Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int 2005; 99: S108.
11. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
12. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
13. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the "troubled" transplant: Data from the DeKAF study. Am J Transplant 2010; 10: 324.
14. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
15. Nickerson P. Post-transplant monitoring of renal allografts: are we there yet? Curr Opin Immunol 2009; 21: 563.
16. Carr MW, Roth SJ, Luther E, et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994; 91: 3652.
17. Allavena P, Bianchi G, Zhou D, et al. Induction of natural killer cell migration by monocyte chemotactic protein-1,-2, and-3. Eur J Immunol 1994; 24: 3233.
18. Wang T, Dai H, Wan N, et al. The role for monocyte chemoattractant protein-1 in the generation and function of memory CD8+ T cells. J Immunol 2008; 180: 2886.
19. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7: 2538.
20. Rush D, Cockfield SM, Nickerson PW, et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation 2009; 88: 897.
21. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010; 90: 394.
22. Susal C, Dohler B, Sadeghi M, et al. Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation 2011; 91: 1364.
23. Nauta FL, Bakker SJ, van Oeveren W, et al. Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 57: 733.
24. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956.
25. Szeto CC, Kwan BC, Lai KB, et al. Urinary expression of kidney injury markers in renal transplant recipients. Clin J Am Soc Nephrol 2010; 5: 2329.
26. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
27. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
28. Ogliari AC, Caldara R, Socci C, et al. High levels of donor CCL2/MCP-1 predict graft-related complications and poor graft survival after kidney-pancreas transplantation. Am J Transplant 2008; 8: 1303.
29. Kruger B, Schroppel B, Ashkan R, et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 2002; 13: 2585.
30. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747.
31. Kurtkoti J, Sakhuja V, Sud K, et al. The utility of 1-and 3-month protocol biopsies on renal allograft function: a randomized, controlled study. Am J Transplant 2008; 8: 317.
32. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129.
33. Hirt-Minkowski P, Amico P, Ho J, et al. Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplant 2012; 12: 1811.
34. Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as a marker of borderline, subclinical and clinical tubulitis. Transplantation 2011; 92: 878.
35. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9: 1347.
36. Solez K, Colvin RB, Racusen LC, et al. Banff 07 Classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
37. Stefura WP, Campbell JD, Douville R, et al. Ultrasensitive ELISA for measurement of human cytokine responses in primary culture. Methods Mol Med 2008; 138: 107.
38. Zheng D, Wolfe M, Cowley BD, et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2003; 14: 2588.
39. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361.